RxDoctor Payments Data

Ben Thomas

Family Medicine · Atlanta, GANPI 1497862593

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $658 of the $804 with a category attached, or 81.8%. Eli Lilly accounts for 81.8% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $708 and has fallen 97.8% since, to $16 in 2025.

$804in general payments, 2019–2025

Across 12 payments — averaging $67.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$658
  • AbbVie$70
  • Alkermes, Inc.$24
  • Novo Nordisk$19
  • Akcea Therapeutics, Inc.$18
  • Medline Industries LP$16
$3,167,333in research payments, 2019–2025

Across 232 payments — averaging $13,652 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$1.6M
  • Regeneron$449K
  • Pfizer$278K
  • Astrazeneca UK Limited$173K
  • Seqirus USA Inc$161K
  • Cue Health Inc.$145K
  • plus $335K from 9 others

What the payments were for

  • Travel & lodging$65882%
  • Food & beverage$14618%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$804 in reported general payments places this provider in the 55th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Other family medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →